HRB Clinical Research Facility, National University of Ireland, H91YR71 Galway, Ireland.
The Norwood Surgery, Southport PR9 7EG, UK.
Int J Environ Res Public Health. 2020 Apr 8;17(7):2557. doi: 10.3390/ijerph17072557.
Low-carbohydrate diets are increasingly used to help patients with obesity and type 2 diabetes. We sought to provide an overview of the evidence for this treatment approach, considering the epidemiology and pathophysiology of obesity and diabetes in terms of carbohydrate excess. We describe the mechanistic basis for the clinical benefits associated with nutritional ketosis and identify areas of practice where the evidence base could be improved. We summarize the key principles which inform our approach to treating patients with low-carbohydrate diets. The scientific controversy relating to these diets is real but is consistent with the known challenges of any dietary interventions and also the limitations of nutritional epidemiology. Secondly, notwithstanding any controversy, international guidelines now recognize the validity and endorse the use of these diets as a therapeutic nutritional approach, in appropriate patients. Thirdly, we have found that early de-prescription of diabetes medications is essential, in particular insulin, sulphonylureas, and sodium-glucose cotransporter (SGLT2) inhibitors. Fourthly, we encourage patients to eat ad libitum to satiety, rather than calorie counting per se. Furthermore, we monitor cardiovascular risk factors frequently, as with all patients with obesity or diabetes, but we do not necessarily consider an increase in low-density lipoprotein (LDL)-cholesterol as an absolute indication to stop these diets, as this is usually related to large LDL particles, which are not associated with increased cardiovascular risk. In the absence of large randomized controlled trials with cardiovascular and other hard endpoints, adopting a low-carbohydrate diet is a legitimate and potentially effective treatment option for patients with diabetes or obesity.
低碳水化合物饮食越来越多地被用于帮助肥胖和 2 型糖尿病患者。我们旨在根据碳水化合物过量的肥胖和糖尿病的流行病学和病理生理学,提供这种治疗方法的证据概述。我们描述了与营养性酮症相关的临床益处的机制基础,并确定了可以改善证据基础的实践领域。我们总结了指导我们用低碳水化合物饮食治疗患者的关键原则。与这些饮食相关的科学争议是真实的,但与任何饮食干预的已知挑战以及营养流行病学的局限性一致。其次,尽管存在争议,但国际指南现在认识到这些饮食的有效性,并认可将其作为一种治疗性营养方法在适当的患者中使用。第三,我们发现早期停用糖尿病药物至关重要,尤其是胰岛素、磺酰脲类药物和钠-葡萄糖共转运蛋白 (SGLT2) 抑制剂。第四,我们鼓励患者随意进食至饱腹感,而不是单纯计算卡路里。此外,我们像所有肥胖或糖尿病患者一样频繁监测心血管危险因素,但我们不一定认为增加低密度脂蛋白 (LDL)-胆固醇是停止这些饮食的绝对指征,因为这通常与大的 LDL 颗粒有关,而大的 LDL 颗粒与增加的心血管风险无关。在没有心血管和其他硬性终点的大型随机对照试验的情况下,采用低碳水化合物饮食是糖尿病或肥胖患者的一种合理且潜在有效的治疗选择。